Targeted therapy plus chemotherapy for EGFR lung cancer that turns small cell
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new targeted therapy (limertinib) combined with standard chemotherapy (carboplatin and etoposide) for people whose EGFR-positive lung cancer has transformed into small cell lung cancer after failing an EGFR inhibitor. The goal is to see if this combination can slow the cancer and help you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have non-small cell lung cancer with an EGFR mutation (like exon 19 deletion or L858R).
- You have taken an EGFR inhibitor, like Tarceva or Tagrisso, and your cancer got worse.
- A biopsy after that progression showed your cancer has turned into small cell lung cancer.
- You have not had chemotherapy for this small cell transformation yet.
- You are in good enough health to be up and about (ECOG performance status 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two combination maintenance drugs (a targeted pill and an anti-angiogenesis drug) for people whose non-small cell lung cancer has turned into small cell lung cancer after EGFR-targeted therapy. The goal is to see if this combination can help keep the cancer under control.
This trial tests a new study drug (PF08634404) combined with standard chemotherapy for people whose non-small cell lung cancer has changed into a more aggressive form called small cell lung cancer. It hopes to improve outcomes by targeting the cancer in two ways.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy can help people with advanced non-small cell lung cancer that carries an EGFR exon 21 mutation and shows PD-L1 expression. The goal is to see if this combination helps shrink tumors or slow cancer growth more effectively.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.